DEA Schedule I placement makes five designer benzodiazepines permanently controlled from 1 April 2026

What the Schedule I placement covers

The rule applies to the named substances and their salts and isomers where applicable. DEA describes them as central nervous system depressants structurally and pharmacologically related to classical benzodiazepines such as alprazolam, with effects including sedation, amnesia and respiratory depression.

For regulated organisations, the practical impact of Schedule I placement is that activities such as manufacture, distribution, reverse distribution, import, export, research, instructional activity, chemical analysis and possession now sit under Schedule I controls on an ongoing basis.

Why DEA acted and what changed from temporary controls

DEA previously issued a temporary Schedule I order on 26 July 2023, later extended until 26 July 2026. The new final rule converts those temporary controls into permanent scheduling following an HHS scientific and medical evaluation (June 2025) and DEA’s eight-factor analysis.

DEA cites three core Schedule I findings: high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. DEA also notes the action supports US obligations under the 1971 UN Convention on Psychotropic Substances, under which these substances were internationally scheduled.

Compliance implications for laboratories, chemical suppliers and logistics

Organisations that may encounter reference standards or research materials should reassess controlled substance governance. DEA highlights requirements spanning registration, security, labelling and packaging, quota (for manufacturers), biennial inventories, records and reporting, and import and export controls.

A practical next step is to map any holdings and workflows involving these substances, confirm registration status where needed, and plan transfers or compliant disposal before the 1 April 2026 effective date.

Summary

DEA’s final rule confirms Schedule I placement for clonazolam, diclazepam, etizolam, flualprazolam and flubromazolam from 1 April 2026. The decision locks in strict, long-term US controls for handling and research, and raises the compliance bar for laboratories, suppliers and logistics teams that may store, test, ship or import these substances.